Pfizer gene therapy for sickle cell receives EU approval

Summary

The European Medicines Agency granted conditional marketing authorization for Pfizer's one-time CRISPR-based gene therapy for sickle cell disease, making it the second approved gene editing treatment in the EU.

Details

Sources (1)

Verification Timeline